michael rawlins chairman, national institute for health and clinical excellence, london emeritus...
Post on 20-Dec-2015
218 views
TRANSCRIPT
![Page 1: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/1.jpg)
Michael RawlinsChairman, National Institute for Health and Clinical Excellence, London
Emeritus Professor, University of Newcastle upon Tyne
Honorary Professor, London School of Hygiene and Tropical Medicine
Rational RationingThe Role of Research
![Page 2: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/2.jpg)
Resource ConstraintsHealthcare Expenditure (US$ per person)
Cos
t (U
S$)
per
per
son
per
year
![Page 3: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/3.jpg)
GDP and Healthcare Expenditure2007
Per capita GDP (Int$)
Pe
r c
ap
ita
he
alt
hc
are
ex
pe
nd
itu
re (
Int$
)
R = 0.776R2 = 0.602
![Page 4: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/4.jpg)
NICE guidance
1. Clinical:– Technology appraisals
– Clinical guidelines
– Interventional procedures
– Medical technologies
– Diagnostics
2. Public health
3. Quality standards and metrics– Quality & Outcomes Framework
– NICE Quality Standards
4. NHS Evidence
![Page 5: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/5.jpg)
NICE guidance
![Page 6: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/6.jpg)
Technology appraisals
Health technologies encompass:– Pharmaceuticals– Devices– Surgical (and other) procedures– Diagnostic methods
Clinic
al e
ffect
iven
ess
Cost e
ffect
iven
ess
![Page 7: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/7.jpg)
Clinical guidelines
“Systematically developed statements to assist
practitioner and patient decisions about
appropriate health care for specific clinical
circumstances”.
Institute of Medicine
Clinic
al e
ffect
iven
ess
Clinic
al e
ffect
iven
ess
Cost e
ffect
iven
ess
Cost e
ffect
iven
ess
![Page 8: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/8.jpg)
Principles
1. Robust
2. Inclusive
3. Transparent
4. Independent
![Page 9: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/9.jpg)
Clinical Evaluation
1. Randomised controlled trials
2. Observational studies
3. Systematic reviews
Avoiding “hiera
rchies” o
f evidence
![Page 10: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/10.jpg)
Randomized controlled trialsadvantages
1. Minimises bias
1. Minimises confounding
1. Minimises random error
![Page 11: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/11.jpg)
Randomized controlled trialsdisadvantages
1. The null hypothesis
2. P-values
3. Generalisability
4. Multiplicity• Stopping rules• Subgroup analyses• Safety analyses
5. Cost
![Page 12: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/12.jpg)
Comparative effectiveness
1. Direct comparisons• A versus B
2. Indirect comparisons• A versus placebo • B versus placebo • Impute A versus B
3. Mixed treatment comparisons
![Page 13: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/13.jpg)
Observational Studies
1. Historical controlled trials
2. Concurrent cohort studies
3. Case-control studies
4. Case series (registries)
5. Case reports
![Page 14: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/14.jpg)
Systematic reviews
Efficacy:– Good at synthesizing RCT evidence– Weak at incorporating observational data
Safety:– Good at synthesizing RCT evidence– Very weak at synthesizing observational data
Cost effectiveness:– Very poor
![Page 15: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/15.jpg)
Economic EvaluationOverarching principles:
1. Economic perspective– NHS and PSS
2. Cost effectiveness– Not affordability or budgetary impact
3. Balance between:– Efficiency (utilitarianism)– Fairness (egalitarianism)
![Page 16: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/16.jpg)
Cost Utility AnalysisCosts (and savings):
– direct– indirect
Benefits:– improvement (change) in HRQoL (utility)– time for which it is “enjoyed”In
crem
ental c
ost effe
ctiveness ra
tio
![Page 17: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/17.jpg)
Cost Ineffectiveness
Probability
of
Rejection
Cost per QALY
A US$ 30,000
B₤45,000
![Page 18: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/18.jpg)
Decision-making1. Scientific judgements
• Reliability of the evidence-base• Appropriateness of sub-groups• Generalisablity• Capture of quality of life• Handling uncertainty
2. Social value judgements• Severity of disease• End of life interventions (“rule of rescue”)• Age• Health inequalities
![Page 19: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/19.jpg)
Social Value Judgements
Citizens Council:– 30 members– Cross-section of England and Wales– Serve for 3 years (one third retiring annually)– Meet twice a year – for 3 days– Deliberative process– Reports directly to the BoardCultu
rally
and context s
pecific
![Page 20: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/20.jpg)
Case-by-Case Decisions
Factors taken into account include:– severity of the underlying condition– extensions to end of life– stakeholder persuasiveness– significant clinical innovation– children– disadvantaged populations– corporate responsibility
![Page 21: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/21.jpg)
Recommendations >£30,000 per QALY
Product Condition QALY(£)
Severity Significant innovation
Riluzole Amyotrophic lateral sclerosis 40,000
Trastuzumab Early breast cancer 37,500
Imatinib Chronic myeloid leukaemia 36,000 to 65,000
Pemetrexed Mesothelioma 34,500
Sunitini Advanced renal carcinoma 50,000
Lenalidomide Multiple myeloma 43,000
![Page 22: Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary](https://reader036.vdocuments.site/reader036/viewer/2022081516/56649d485503460f94a23d46/html5/thumbnails/22.jpg)
Conclusions
1. Rationing can (and should) be rational
2. Research methodology needs improving• less resource-intensive approaches to RCTs• creative use of observational data• capture the potential of digital technology
3. Earn and retain the trust of all our stakeholders